SSG
AMRX icon

Summit Securities Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Summit Securities Group’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,955
Closed -$32K – 1013
2025
Q2 		$32K Buy
+3,955
New +$29.8K 0.01% 607

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Summit Securities Group's AMRX Position: Q3 2025 in Review

Summit Securities Group sold out of Amneal Pharmaceuticals (AMRX) in Q3 2025, closing a stake of 3,955 shares — an estimated $32K sold.

Summit Securities Group first reported a position in AMRX in Q2 2025 and held it in 1 quarter. The position peaked at $32K in Q2 2025. 248 funds tracked by Wall St. Rank hold AMRX as of Q3 2025.

  • Summit Securities Group reported no remaining Amneal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 3,955 Amneal Pharmaceuticals shares in Q3 2025, an estimated $32K.
  • Summit Securities Group first reported a position in Amneal Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Summit Securities Group's Amneal Pharmaceuticals position peaked at $32K in Q2 2025.
  • 248 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.